GSK agrees $10 billion deal for Nuvalent cancer drugs
By 
Phillip Broadwith2026-06-16T10:52:00
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
GSK has agreed to buy US cancer biotech firm Nuvalent for over $10 billion (£8 billion). The deal gives GSK two late-stage lung cancer drugs: zidesamtinib and neladalkib, both of which are on expedited regulatory pathways with the US Food and Drug Administration, with an approval decision on zidesamtinib scheduled for September.